Nasdaq:US$32.30 (+0.56) | HKEX:HK$49.55 (-1.35) | AIM:£4.69 (-0.02)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 16 Oct 2010

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor